Escape Room

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
水曜日, 5月 8, 2024
CTA, CD22, HIP, Contingency, Cell Stem Cell, CD47, Lupus nephritis, Cell, Insulin, Safety, ANCA, Organoid, Research, Survival, Immunosuppression, Research and development, B cell, Development, VIVID, GLEAM, Administration, Autoimmunity, Exercise, Biotechnology, CD19, Patent, Sana, Patient, Regeneration, NHP, Diabetes, Cancer, Lymphoid leukemia, GAAP, Organization, Escape Room, Vaccine

Enrollment in this study continues, and Sana expects to share more data in 2024.

Key Points: 
  • Enrollment in this study continues, and Sana expects to share more data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects to share initial data in the first half of 2024.

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
水曜日, 5月 8, 2024
Research, Patient, Melanoma, Therapy, ACHL, NSCLC, G&A, Escape Room, Pharmaceutical industry

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights.

Key Points: 
  • LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights.
  • These data continue to inform the development of cNeT and potentially other modalities like neoantigen vaccines and TCR-T therapies,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics.
  • Research and development (R&D) expenses: R&D expenses were $10.1 million for the first quarter ended March 31, 2024, a decrease of $3.7 million compared to $13.9 million for the first quarter ended March 31, 2023.
  • General and administrative (G&A) expenses: G&A expenses were $4.2 million for the first quarter ended March 31, 2024, a decrease of $0.5 million compared to $4.7 million for first quarter ended March 31, 2023.

New Discovery Identifies “Don’t Eat Me” Protein that Allows Lyme Bacteria to Evade Body’s Immune Response

Retrieved on: 
火曜日, 5月 7, 2024
SIRP, Stanford University, Massachusetts Institute of Technology, University, Cancer, CD47, Hope, Infection, Regenerative medicine, CD24, Bacteria, MD, Doctor of Philosophy, Research, Borrelia burgdorferi, Therapy, Atherosclerosis, Lyme disease, Patient, Macrophage, PALO, Diagnosis, BioRxiv, BAL, Immune system, P66, Escape Room, Vaccine

The research was conducted at Stanford University and University of California San Francisco and funded in part by Bay Area Lyme Foundation.

Key Points: 
  • The research was conducted at Stanford University and University of California San Francisco and funded in part by Bay Area Lyme Foundation.
  • This groundbreaking data posted on bioRxiv on April 30, 2024, is expected to be published in a peer-review journal in the future.
  • “One of the big mysteries of Lyme disease has been how Borrelia is able to evade and survive the immune system – and this study helps answer that question.
  • “Patients need both a robust immune response and antibiotics to eradicate an infection - antibiotics alone are not usually sufficient.

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Retrieved on: 
木曜日, 5月 2, 2024
Oncology, Health, Other Health, General Health, Research, Science, Pharmaceutical, FDA, Cancer, Safety, CD4, Serum, Carcinoma in situ, MHC, Grand Bahama International Airport, Vaccine, BCG, SII, Merck & Co., CIS, Patient, Medicine, NMIBC, Standard of care, Neoplasm, GMP, Bladder cancer, Serum Institute of India, CD8, Escape Room

ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).

Key Points: 
  • ImmunityBio, Inc. ( NASDAQ: IBRX ), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).
  • Increasing the available supply of BCG is intended to address shortages for the combination therapy with ANKTIVA.
  • “The collaboration between Serum Institute of India and ImmunityBio will undoubtedly transform the way we approach cancer treatment.
  • We look forward to exploring ANKTIVA in combination with BCG in non-muscle invasive bladder cancer (NMIBC) and across other tumor types.

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Retrieved on: 
木曜日, 4月 25, 2024
PFS, Efficacy, Safety, DCR, Risk, Nivolumab, Randomness, SOC, Drug resistance, Death, CM24, Tumor microenvironment, OS, PD-1, PDAC, ASCO, Cancer, Patient, Society, CA19-9, Interim, BMS, Neoplasm, Bristol Myers Squibb, Annual general meeting, Pharmacodynamics, Escape Room, Pharmaceutical industry

REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that interim results from its randomized, controlled, open label, multicenter Phase 2 study of CM24, a first in class immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC), have been selected as late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting which will take place on May 31 – June 4, 2024 in Chicago, Illinois.

Key Points: 
  • The primary endpoint of the study is overall survival (OS), with progression free survival (PFS) and objective response rate (ORR) as secondary endpoints.
  • The study was designed as Bayesian to evaluate the potential benefit of the experimental arm vs SoC and is not powered for hypothesis testing.
  • Approximately 60 patients have been enrolled in the randomized study in 18 centers in the U.S., Spain and Israel.
  • “We are honored to be selected by the ASCO committee with our late breaking abstract poster presentation and are looking forward to presenting our interim results from our randomized Phase 2 CM24 study at the ASCO 2024 annual meeting.” stated Gil Efron, Chief Executive Officer of Purple Biotech.

Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology

Retrieved on: 
木曜日, 4月 18, 2024
Organization, Safety, IPS, Partnership, Panasonic, Cell, Research, Entrepreneurship, Engineering, Nobel, Patient, IPSC, Bone marrow, CIRA, Health, Therapy, Biotechnology, SAN, Escape Room, Pharmaceutical industry

SAN FRANCISCO and KYOTO, Japan, April 18, 2024 /PRNewswire/ -- Shinobi Therapeutics, a biotechnology company developing a new class of immune evasive iPS cell therapies, today announced a partnership with Panasonic Holdings Corp and Kyoto University's Center for iPS Cell Research and Application (CiRA).

Key Points: 
  • SAN FRANCISCO and KYOTO, Japan, April 18, 2024 /PRNewswire/ -- Shinobi Therapeutics, a biotechnology company developing a new class of immune evasive iPS cell therapies, today announced a partnership with Panasonic Holdings Corp and Kyoto University's Center for iPS Cell Research and Application (CiRA).
  • Through this strategic collaboration, the organizations aim to engineer a novel manufacturing platform to produce iPS-T cell therapies more efficiently and at lower cost than is possible with currently available technology.
  • "Advancements in iPS cell production and Shinobi's genetic modification of iPSCs for immune evasion have made regenerative T cell therapy increasingly feasible," said Shin Kaneko, Co-Founder at Shinobi.
  • The newly announced partnership will leverage Panasonic's manufacturing expertise to develop a new method of producing iPS-T cell therapies in a closed-system process.

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
金曜日, 4月 5, 2024
CDTX, Colorectal cancer, Drug, Adenosine, Patient, SAN, Tavarua, AACR, Therapy, Cancer, Pathology, CCR5, CD73, DFC, San Diego Convention Center, Oleclumab, Escape Room, Vaccine

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced the company will deliver four poster presentations, including one late-breaking poster presentation, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.

Key Points: 
  • The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • “Our Cloudbreak platform has quickly produced DFC candidates effective in preclinical studies across various cancers with specific disease targets.
  • This week, we are sharing data on our CCR5 DFC program for the first time, which has demonstrated robust efficacy as a monotherapy in mouse models of colorectal cancer.
  • Targeting CCR5 has the potential to improve response rates to immune checkpoint inhibitor therapies, which could have a greater impact for patients unresponsive to these current treatment options.

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Retrieved on: 
木曜日, 4月 4, 2024
Research, Virtual, NSCLC, Immunotherapy, TIL, Patient, G&A, Allele, ACHL, HLA, Neoplasm, Therapy, Event, Safety, Melanoma, Patent, Escape Room, Cryptocurrency

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

Key Points: 
  • These learnings will inform the development of cNeT and related neoantigen vaccine and TCR-T therapies,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics.
  • Research and development (R&D) expenses: R&D expenses were $15.9 million for the fourth quarter ended December 31, 2023, a decrease of $3.0 million compared to $18.9 million for the fourth quarter ended December 31, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $3.6 million for the fourth quarter ended December 31, 2023, a decrease of $0.4 million compared to $4.0 million for December 31, 2022.
  • Net loss: Net loss for the fourth quarter ended December 31, 2023 was $18.6 million or $0.46 per share compared to $24.1 million or $0.61 per share for the fourth quarter ended December 31, 2022.

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Retrieved on: 
木曜日, 4月 4, 2024
Lymphocytopenia, Neutropenia, NSCLC, TIL, Patient, ACHL, Therapy, Safety, Melanoma, Blood, Escape Room

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma. The update includes data from 18 patients across CHIRON (n=12) and THETIS (n=6) dosed since the previous interim update in December 2022, with two CHIRON patients and one THETIS patient having received enhanced chemo-conditioning and IL-2 dosing aligned to standard tumor infiltrating lymphocyte (TIL) therapy (enhanced host conditioning) in a new Cohort C. This new Cohort C will allow the impact of enhanced host conditioning on cNeT engraftment and persistence beyond 28 days to be evaluated.

Key Points: 
  • All trial participants were late-stage, checkpoint refractory patients with progressive disease at the time of lymphodepletion.
  • The observed tolerability profiles remain favorable and similar to standard TIL therapy.
  • These learnings will inform the development of cNeT and related neoantigen vaccine and TCR-T therapies,” said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • “We have made important progress in the optimization of our VELOS manufacturing process with a significant improvement in cNeT doses delivered and are developing our understanding of the relationship between host conditioning and the engraftment of infused cNeT.

iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024

Retrieved on: 
水曜日, 4月 3, 2024
Apollon, Apoptosis, Tumor microenvironment, Cancer, Abstract, AACR, Therapy, Escape Room, Pharmaceutical industry

MARTINSRIED, Germany and MUNICH, Germany, April 03, 2024 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a clinical-stage biopharmaceutical company translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, today announces that it will present new data on its lead I/O drug candidates OMX-0407 and IOMX-0675, plus its proprietary iOTarg™ screening platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place from April 5-10, 2024, in San Diego, California.

Key Points: 
  • "We are excited to share updates on our two lead I/O programs targeting a broad range of solid tumor indications and our high-throughput target screening platform – iOTarg.
  • Through tyrosine kinase signaling, OMX-0407 interferes with cell cycle regulation and cancer cell proliferation.
  • Complementary to this direct mode of action, OMX-0407 also potentiates tumor cell apoptosis in response to death receptor ligands including tumor necrosis factor through salt inducible kinase signaling.
  • With this dual mode of action, OMX-0407 has shown striking single-agent efficacy in multiple pre-clinical tumor models.